APPROVAL OF THE GOVERNMENT Sample Clauses

APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and giving this Agreement full force and effect of law notwithstanding any countervailing Governmental enactment, and the Agreement is signed by the GOVERNMENT, GANOPE, and CONTRACTOR . ……………………………………………… BY ……………………………………………… BY South Valley Egyptian Petroleum Holding Company BY THE ARAB REPUBLIC OF EGYPT BY DATE ANNEX "A" CONCESSION AGREEMENT BETWEEN THE ARAB REPUBLIC OF EGYPT AND South Valley Egyptian Petroleum Holding Company AND ---------------------------------------. AND ---------------------------------------. IN -------------------------------------- Area AT ----------------------------------- A.R.E. ـــــــــــــــــــــــــــــــــــــــــــــــــ BOUNDARY DESCRIPTION OF THE CONCESSION Area Annex "B" is a provisional illustrative map at an approximate scale of 1 showing the Area covered and affected by this Agreement. The Area measures approximately ------------- square kilometers of surface Area. It is composed of all or part of Exploration Blocks, the whole Blocks are defined on three (3) minutes latitude by three (3) minutes longitude grid. It is to be noted that the delineation lines of the Area in Annex "B" are intended to be only illustrative and provisional and may not show accurately their true position in relation to existing monuments and geographical features. Coordinates of the corner points of the Area are given in the following table which forms an integral part of Annex "A":- BOUNDARY COORDINATES OF -------------------------------- Area AT ------------------------------------------------ Point Latitude/ N Longitude/ E DUE 5 6 ANNEX “B” Map of Concession Agreement ----------------------------- Area Scale 1 :……………. " B"ANNEX PETROLEUM CONCESSION AGREEMENT BETWEEN ARAB REPUBLIC OF EGYPT AND South Valley Egyptian Petroleum Holding Company AND ــــــــــــــــــــــــــــــــــــــــــــــ AND IN -----------------AREA AT ---------------------- .A. R. E Scale 1: ……….. "ب" قحلم مازتلا ةيقافتا ينب .ع.م.ج و لوتربلل ةضباقلا ةيرصلما ىداولا بونج ةكرش و -------------- ةكرش و -------------- ةكرش -----------ةقطنم في -----------ب ع.م.ج ………. : 1 مسر سايقم ANNEX "C" Letter of Guarantee Letter of Guarantee No. ----- (Cairo 20 ) South Valley Egyptian Petroleum Holding Company Gentlemen , The undersigned, National Bank of Egypt / or any first class si...
Sample 1See All (6)
AutoNDA by SimpleDocs
APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and giving this Agreement full force and effect of law notwithstanding any countervailing Governmental enactment , and the Agreement is signed by the GOVERNMENT, EGPC, and CONTRACTOR. ------------------------------------------------- In his capacity Name: By: EGYPTIAN GENERAL PETROLEUM CORPORATION In his capacity Name: By: ARAB REPUBLIC OF EGYPT In his capacity Name: By: DATE: ANNEX "A" CONCESSION AGREEMENT BETWEEN THE ARAB REPUBLIC OF EGYPT AND THE EGYPTIAN GENERAL PETROLEUM CORPORATION AND ------------------------------------------------ IN -------------------------------- AREA ------------------------------------------------ A.R.E. BOUNDARY DESCRIPTION OF THE CONCESSION AREA Annex "B" is a provisional illustrative map at an approximate scale of 1 showing the Area covered and affected by this Agreement. - The Area measures approximately square kilometers and ---------------------------- square meters ( km2) of surface Area. It is composed of all or part of Exploration Blocks, the whole Blocks are defined on three
Sample 1Sample 2Sample 3
APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and F giving this Agreement full force and effect of law, notwithstanding any countervailing governmental enactment, and the Agreement is signed by the GOVERNMENT, EGPC, and CONTRACTOR. NATIONAL EXPLORATION COMPANY BY: -------------------------------- EGYPTIAN GENERAL PETROLEUM CORPORATION BY: -------------------------------- ARAB REPUBLIC OF EGYPT BY: -------------------------------- DATE: ------------------------------ 51 Central Sinai Concession 20F </TEXT> </DOCUMENT>
Sample 1
APPROVAL OF THE GOVERNMENT. 72 ANNEXES TO THE CONCESSION AGREEMENT ANNEXES TITLE PAGE ANNEX “A” BOUNDARY DESCRIPTION OF THE CONCESSION AREA74 ANNEX “B” MAP OF THE CONCESSION AGREEMENT 76 ANNEX "C-1" BANK LETTER OF GUARANTEE 77 ANNEX "C-2" Production LETTER OF GUARANTEE 79 ANNEX "D" CHARTER OF THE JOINT VENTURE COMPANY 81 ANNEX "E" ACCOUNTING PROCEDURE 85 ANNEX "F" DEVELOPMENT LEASE ABANDONMENT COST RECOVERY MECHANISM 99 ANNEX "G" Map of the National Gas pipeline Grid System 103 Map of Crude and Condensate Pipeline Network 103 Map of LPG Pipeline Network 103 CONCESSION AGREEMENT FOR GAS AND CRUDE OIL EXPLORATION AND EXPLOITATION BETWEEN THE ARAB REPUBLIC OF EGYPT AND THE EGYPTIAN NATURAL GAS HOLDING COMPANY AND -------------------------------------- AND -------------------------------------------------------- AND ----------------------------------------------------- IN ------------------------- AREA ----------------------------- A.R.E. This Agreement made and entered on this ------ day of ------201--, by and between the ARAB REPUBLIC OF EGYPT (hereinafter referred to variously as the "A.R.E." or as the "GOVERNMENT"), the EGYPTIAN NATURAL GAS HOLDING COMPANY, a legal entity created by the Prime Minister Decree No. 1009 of 2001, as amended, and according to Law No. 203 of 1991, as amended (hereinafter referred to as "EGAS"), ----------------- ---------- a -------------- company organized and existing under the laws of ---- ------------------------ (hereinafter referred to as “---------------”) or CONTRACTOR. , a company organized and existing under the laws of ---------------- (hereinafter referred to as “ ”) and , a company organized and existing under the laws of --------------- (hereinafter referred to as “ ”). , and shall be hereinafter referred to collectively as "CONTRACTOR" and individually as “Contractor Member”.
Sample 1
APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and giving this Agreement full force and effect of law notwithstanding any countervailing Governmental enactment, and the Agreement is signed by the GOVERNMENT, EGPC, and CONTRACTOR. DOVER INVESTMENTS LIMITED BY: EGYPTIAN GENERAL PETROLEUM CORPORATION BY: ARAB REPUBLIC OF EGYPT BY: DATE : 51 ANNEX "A" CONCESSION AGREEMENT BETWEEN THE ARAB REPUBLIC OF EGYPT AND EGYPTIAN GENERAL PETROLEUM CORPORATION. AND DOVER INVESTMENTS LIMITED IN EAST WADI ARABA AREA GULF OF SUEZ A.R.E. BOUNDARY DESCRIPTION OF THE CONCESSION AREA Annex "B" is a provisional illustrative map at an approximate scale of
Sample 1
APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and giving this Agreement full force and effect of law notwithstanding any countervailing Governmental enactment, and the Agreement is signed by the GOVERNMENT, EGPC and CONTRACTOR. TRANSGLOBE WEST GHARIB Inc. By Mr.: [redacted] In his capacity: [redacted] Signature: "signed" TRANSGLOBE WEST BXXX Inc. By Mr.: [redacted] In his capacity: [redacted] Signature: "signed" TG NX XXXXXX Inc. By Mr.: [redacted] In his capacity: [redacted] Signature: "signed" EGYPTIAN GENERAL PETROLEUM CORPORATION By Mr.: [redacted] In his capacity: [redacted] Signature: "signed" ARAB REPUBLIC OF EGYPT By His Excellency : [redacted] In his capacity: [redacted] Signature: "signed" Date: January 19, 2022 ANNEX "A" CONCESSION AGREEMENT FOR PETROLEUM EXPLORATION, DEVELOPMENT AND EXPLOITATION BETWEEN THE ARAB REPUBLIC OF EGYPT AND THE EGYPTIAN GENERAL PETROLEUM CORPORATION AND TRANSGLOBE WEST BXXX Inc. AND TRANSGLOBE WEST GHARIB Inc. AND TG NX XXXXXX Inc. IN MERGED DEVELOPMENT AREAS WEST BXXX AREA WEST GHARIB AREA NORTHWEST GHARIB ONSHORE AREA EASTERN DESERT
Sample 1
APPROVAL OF THE GOVERNMENT. This Agreement shall not be binding upon any of the parties hereto unless and until a law is issued by the competent authorities of the A.R.E. authorizing the Minister of Petroleum to sign this Agreement and giving this Agreement full force and effect of law notwithstanding any countervailing governmental enactment, and the Agreement is signed by the GOVERNMENT, EGAS and CONTRACTOR. BY: ................................................ BY: ................................................ BY: ................................................
Sample 1
AutoNDA by SimpleDocs

Related to APPROVAL OF THE GOVERNMENT

  • No Government Approval You understand that no state or federal authority has reviewed this Investment Agreement or the Note or made any finding relating to the value or fairness of the investment.

  • Approval of Listing At the Closing Time, the Securities shall have been approved for listing on the New York Stock Exchange, subject only to official notice of issuance.

  • Actions Before Governmental Authorities There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.

  • No Governmental Prohibition No order, statute, rule, regulation, executive order, injunction, stay, decree, judgment or restraining order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory authority or instrumentality which prohibits the consummation of the transactions contemplated hereby.

  • Regulatory Applications (a) Sky and SBI and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare, within 45 days of the execution of this Agreement, all documentation and requests for regulatory approval, to timely effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities and Regulatory Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Sky and SBI shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, and shall be provided in advance so as to reasonably exercise its right to review in advance, all material written information submitted to any third party or any Governmental Authority or Regulatory Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities or Regulatory Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.

  • Compliance with Government Regulations The Company covenants that if any share of Common Stock required to be reserved for purposes of exercise or conversion of Warrants require, under any federal or state law or applicable governing rule or regulation of any national securities exchange, registration with or approval of any governmental authority, or listing on any such national securities exchange, before such shares may be issued upon exercise, the Company will use its commercially reasonable efforts to cause such shares to be duly registered, approved or listed on the relevant national securities exchange, as the case may be.

  • Approval of Counsel The exercise of the Option and the issuance and delivery of shares of Class A Stock pursuant thereto shall be subject to approval by the Corporation's counsel of all legal matters in connection therewith, including, but not limited to, compliance with the requirements of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the Class A Stock may then be listed.

  • Waiver of Notice; Approval of Meeting; Approval of Minutes The transactions of any meeting of Limited Partners, however called and noticed, and whenever held, shall be as valid as if it had occurred at a meeting duly held after regular call and notice, if a quorum is present either in person or by proxy. Attendance of a Limited Partner at a meeting shall constitute a waiver of notice of the meeting, except when the Limited Partner attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened; and except that attendance at a meeting is not a waiver of any right to disapprove the consideration of matters required to be included in the notice of the meeting, but not so included, if the disapproval is expressly made at the meeting.

  • No Government Recommendation or Approval The Subscriber understands that no federal or state agency has passed upon or made any recommendation or endorsement of the offering of the Shares.

Time is Money Join Law Insider Premium to draft better contracts faster.